NEW YORK, June 28 (GenomeWeb News) - AstraZeneca has installed several of Cellectricon's DynaFlow ion channels screening platforms worldwide, Cellectricon said today.
Cell-Based Assay News, a GenomeWeb News sister publication, reported in June 2004 that AstraZeneca had decided to use DynaFlow in its ion channel drug-discovery program. Cellectricon said today that AstraZeneca has placed multiple orders for DynaFlow systems since that time.
Financial terms of the deal were not disclosed.
DynaFlow is based on a computer-controlled microfluidic chip, and is designed to be used with any cell, patch-clamp configuration, active substance, and ion channel, Cellectricon said.